Replies to post #91325 on Biotech Values

[DewDiligence]

IDIX Major Shareholders

[Updated for new diluted share count.]


The percentages shown below are based on 78.9.M diluted shares for valuation purposes
(#msg-49785732), and hence they differ from the percentages reported in SEC filings.

 
                      Shares    Stake 
 Novartis           31,322,836† 39.7% 
 JP Sommadossi (CEO) 4,226,000*  5.4% 
 BB/MPM Capital      3,321,534   4.2% 
 GlaxoSmithKline     2,474,527   3.1% 

*Includes all 2.2M options, whether or not vested.

†NVS has the contractual right to make small “true up” purchases from time to time to offset option exercises by IDIX’s employees and thereby maintain a constant equity stake. The price paid by NVS for these shares is the average exercise price of the small number of options in question.